artus gains worldwide PCR (Polymerase Chain Reaction) licence:
This article was originally published in Clinica
German biotechnology company artus has been granted a licence for the worldwide commercial use of the Polymerase Chain Reaction (PCR) technology by Hoffmann-La Roche. Hamburg-based artus, which specialises in pathogen diagnosis through genetic procedures, will now be able to manufacture and market diagnostic products based on PCR, for the detection of herpes viruses and other infectious diseases. In addition to PCR detection procedures using gels, artus is intensifying research into real-time systems that enable rapid, quantitative and reliable pathogen detection.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.
Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.